JPS6227048B2 - - Google Patents
Info
- Publication number
- JPS6227048B2 JPS6227048B2 JP53134026A JP13402678A JPS6227048B2 JP S6227048 B2 JPS6227048 B2 JP S6227048B2 JP 53134026 A JP53134026 A JP 53134026A JP 13402678 A JP13402678 A JP 13402678A JP S6227048 B2 JPS6227048 B2 JP S6227048B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- cells
- human
- sensitive
- sensitive disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000014150 Interferons Human genes 0.000 claims description 134
- 108010050904 Interferons Proteins 0.000 claims description 134
- 229940079322 interferon Drugs 0.000 claims description 134
- 241001465754 Metazoa Species 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000009792 diffusion process Methods 0.000 claims description 17
- 230000001064 anti-interferon Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 9
- 239000002799 interferon inducing agent Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000003405 preventing effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 98
- 238000004519 manufacturing process Methods 0.000 description 35
- 238000000034 method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 19
- 230000016396 cytokine production Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 4
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- -1 Since its discovery Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000002554 disease preventive effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- WVULZDFWPQCPPJ-UHFFFAOYSA-N potassium;hydrochloride Chemical compound Cl.[K] WVULZDFWPQCPPJ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13402678A JPS5562024A (en) | 1978-10-31 | 1978-10-31 | Preventive and remedy for interferon-sensitive disease |
| GB7901089A GB2016015B (en) | 1978-01-22 | 1979-01-11 | Method of preparing interferon and preparations containing interferon |
| AU43345/79A AU533201B2 (en) | 1978-01-22 | 1979-01-12 | Interferon |
| NO790195A NO152976C (no) | 1978-01-22 | 1979-01-19 | Fremgangsmaate for fremstilling av interferon. |
| SE7900493A SE436969B (sv) | 1978-01-22 | 1979-01-19 | Sett att framstella humanspecifikt interferon |
| DK025579A DK153848C (da) | 1978-01-22 | 1979-01-19 | Fremgangsmaade til fremstilling af interferon |
| DE2902136A DE2902136C2 (de) | 1978-01-22 | 1979-01-19 | Verfahren zum Herstellen von Interferon |
| CH54179A CH637831A5 (fr) | 1978-01-22 | 1979-01-19 | Procede de preparation d'interferon et preparation le contenant. |
| IT47712/79A IT1116493B (it) | 1978-01-22 | 1979-01-19 | Procedimento per la produzione di interferon e composizioni che lo contengono |
| FR7901324A FR2414920A1 (fr) | 1978-01-22 | 1979-01-19 | Interferon et preparation le contenant |
| FI790188A FI66428C (fi) | 1978-01-22 | 1979-01-19 | Foerfarande foer framstaellning av maenniskospecifikt interferon |
| CA000320042A CA1135186A (en) | 1978-01-22 | 1979-01-22 | Process for the production of human interferon |
| ES477060A ES477060A1 (es) | 1978-01-22 | 1979-01-22 | Un metodo para la preparacion de interferon. |
| MX10116779U MX6025E (es) | 1978-01-22 | 1979-01-22 | Procedimiento mejorado para la produccion de interferon especifico para humanos |
| NL7900476A NL192086C (nl) | 1978-01-22 | 1979-01-22 | Werkwijze ter bereiding van interferonen en werkwijze ter bereiding van een geneesmiddel dat interferonen bevat. |
| US06/005,585 US4276282A (en) | 1978-01-22 | 1979-01-22 | Interferon and preparations containing interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13402678A JPS5562024A (en) | 1978-10-31 | 1978-10-31 | Preventive and remedy for interferon-sensitive disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5562024A JPS5562024A (en) | 1980-05-10 |
| JPS6227048B2 true JPS6227048B2 (nl) | 1987-06-12 |
Family
ID=15118631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13402678A Granted JPS5562024A (en) | 1978-01-22 | 1978-10-31 | Preventive and remedy for interferon-sensitive disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5562024A (nl) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63152456U (nl) * | 1987-03-26 | 1988-10-06 | ||
| JPS63155475U (nl) * | 1987-03-31 | 1988-10-12 | ||
| JPS63183844U (nl) * | 1987-05-19 | 1988-11-25 | ||
| JPH04136163U (ja) * | 1991-06-07 | 1992-12-17 | 株式会社コメツトデザイン研究所 | ベツト用暖房付きマツトレス |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5825439B2 (ja) * | 1980-12-30 | 1983-05-27 | 株式会社林原生物化学研究所 | ヒト副甲状腺ホルモンの製造方法 |
| WO1982000588A1 (en) * | 1980-08-22 | 1982-03-04 | Illinois Univ | Delivery of biologically active components of heterologous species interferon isolates |
| JPS609795B2 (ja) * | 1980-12-11 | 1985-03-13 | 株式会社林原生物化学研究所 | ヒト上皮細胞成長因子の製造方法 |
| JPH0764744B2 (ja) * | 1981-11-21 | 1995-07-12 | 株式会社林原生物化学研究所 | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 |
| CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
| JPS61263929A (ja) * | 1986-04-30 | 1986-11-21 | Hayashibara Takeshi | 抗タイプ２インターフェロン感受性疾患剤 |
| CA1321347C (en) * | 1986-11-10 | 1993-08-17 | David C. Munch | Human leukocyte interferon composition and skin treatment |
| EP0276120B1 (en) * | 1987-01-20 | 1992-04-08 | Schering Corporation | Treatment of certain leukemias with a combination of gamma interferon and alpha interferon |
| JP4610154B2 (ja) * | 2002-05-30 | 2011-01-12 | 大塚製薬株式会社 | 注射用製剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50100223A (nl) * | 1974-01-11 | 1975-08-08 | ||
| JPS5191319A (en) * | 1974-04-03 | 1976-08-10 | Intaafueronno saikatsuseikaho | |
| JPS5654158A (en) * | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
-
1978
- 1978-10-31 JP JP13402678A patent/JPS5562024A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50100223A (nl) * | 1974-01-11 | 1975-08-08 | ||
| JPS5191319A (en) * | 1974-04-03 | 1976-08-10 | Intaafueronno saikatsuseikaho | |
| JPS5654158A (en) * | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63152456U (nl) * | 1987-03-26 | 1988-10-06 | ||
| JPS63155475U (nl) * | 1987-03-31 | 1988-10-12 | ||
| JPS63183844U (nl) * | 1987-05-19 | 1988-11-25 | ||
| JPH04136163U (ja) * | 1991-06-07 | 1992-12-17 | 株式会社コメツトデザイン研究所 | ベツト用暖房付きマツトレス |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5562024A (en) | 1980-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS631296B2 (nl) | ||
| DK153848B (da) | Fremgangsmaade til fremstilling af interferon | |
| JPS6045849B2 (ja) | ヒトエリトロポエチンの製造方法 | |
| JPS6030654B2 (ja) | ヒトコロニ−刺激因子の製造方法 | |
| JPS6227048B2 (nl) | ||
| JPS5852634B2 (ja) | ウロキナ−ゼの製造法 | |
| JPS586475B2 (ja) | ヒト絨毛性性腺刺激ホルモンの製造方法 | |
| GB2083826A (en) | Process for the production of human insulin | |
| JPS6011890B2 (ja) | ツモアネクロシスフアクタ−の製造方法 | |
| JPS6245208B2 (nl) | ||
| KR820001174B1 (ko) | 사람 특이성 인터페론의 제조법 | |
| JPS6323176B2 (nl) | ||
| JPS5816687A (ja) | リンホトキシンの製造方法 | |
| JPS5825440B2 (ja) | ヒトカルシトニンの製造方法 | |
| KR970002165B1 (ko) | γ-인터페론의 제조방법과 그 용도 | |
| KR830001817B1 (ko) | 타이프ⅱ 인터페론의 제조방법 | |
| JP2926409B2 (ja) | 癌転移抑制因子の製造方法 | |
| JPH0764744B2 (ja) | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 | |
| JPS5815921A (ja) | 抗リンホトキシン感受性疾患剤 | |
| JP2850293B2 (ja) | γ−インターフェロン感受性疾患剤 | |
| JPS6045850B2 (ja) | ヒト副腎皮質刺激ホルモンの製法 | |
| JPH0631318B2 (ja) | 新リンホカインｉｉｉとその製法 | |
| JPS58138395A (ja) | ヒト免疫応答抑制因子の製造方法 | |
| JPH0527640B2 (nl) | ||
| JPS62223196A (ja) | 精製されたヒト ツモア・ネクロシス・フアクタ− |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |